AI Insight
Researchers from the Alzheimer's Disease Sequencing Project developed a systematic two-phase framework to evaluate and rank genetic evidence for Alzheimer's disease and related dementias. By reviewing 29 large-scale genome-wide studies published since 2015, they identified 111 high-confidence genetic loci with replicated associations across multiple ancestries and converging lines of evidence. The prioritized loci implicate key biological pathways including amyloid precursor protein processing, microglial immune function, and lipid metabolism, including genes not previously captured by existing genetic databases.
Why it matters
This rigorously curated catalog provides researchers and drug developers with a more reliable foundation for functional validation studies and therapeutic target discovery in Alzheimer's disease. The publicly accessible resource may accelerate identification of drug candidates and offers a methodological model applicable to genetic research in other complex diseases.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: The Alzheimer’s Disease Sequencing Project Gene Verification Committee developed a systematic framework to adjudicate genetic evidence for AD and related dementias, addressing wide variation in association quality. Methods: Phase 1 established tiered criteria by evaluating 23 nominated loci across study designs. Phase 2 applied this framework to 29 large-scale genome-wide studies published since 2015, tiering 163 unique loci. Results: Phase 1 yielded 17 high-confidence loci (12 linked to specific genes), and Phase 2 identified 111 high-confidence loci/genes with replicated associations across ancestries and convergent single-variant/variant-set evidence. Prioritized loci highlight APP processing, microglial immunity, and lipid metabolism pathways, including genes not captured by existing resources like Agora or Open Targets. Summarized results can be viewed at https://topgenes.niagads.org/. Conclusion: This rigorously adjudicated catalog represents the most comprehensive AD/ADRD genetics resource to date, providing a foundation for functional validation and therapeutic discovery with broad applicability to complex diseases.